Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell ...
Martinsried/Munich, October 1, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) and three private investors have founded Immunocore Ltd, which will focus on the technology platform for monoclonal ...
Medigene has agreed to expand its nearly two-year-old, up-to-$1 billion-plus cancer immunotherapy collaboration with bluebird bio, saying today that the expansion could generate up to $509 ...
Medigene's (DE: MDG1k) H1 results are in line with our expectations and represent the completion of its transformation into a prominent T-cell immunotherapy player. Highlights from H1 include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results